甲状腺功能亢进患者中，甲巯咪唑（卡比马唑的一种代谢产物）的血浆浓度。
Plasma concentrations of methimazole, a metabolite of carbimazole, in hyperthyroid patients.
机构信息
Drug Metabolism Unit, Department of Pharmaceutical Chemistry, University of Strathclyde, Glasgow, Scotland.
出版信息
Br J Clin Pharmacol. 1974 Jun;1(3):265-9. doi: 10.1111/j.1365-2125.1974.tb00248.x.
Abstract
1 Carbimazole was administered to nine hyperthyroid patients, and blood samples were taken at various time intervals for analysis of carbimazole, and its metabolite methimazole.2 A technique was developed for the measurement of methimazole in serum using a High-Pressure Liquid Chromatograph, which could detect nanogram quantities of this metabolite.3 After a single oral dose, the patients' blood levels appeared to fall into two groups, either those with a maximum concentration of methimazole between 30 and 60 min, or those whose maximum was 2 to 3 hours.4 The results would suggest that there could be a correlation between the high level of methimazole in serum and the high thyroxine concentration found in some patients.
摘要
卡比马唑给 9 位甲状腺功能亢进患者服用，在不同时间间隔采血样，分析卡比马唑及其代谢产物甲巯咪唑。
建立了一种高效液相色谱法测定血清中甲巯咪唑的方法，能够检测到这种代谢物的纳克数量。
单次口服后，患者的血药浓度似乎分为两组，一组患者的甲巯咪唑最大浓度在 30 至 60 分钟之间，另一组患者的最大浓度在 2 至 3 小时之间。
结果表明，血清中甲巯咪唑水平高与某些患者甲状腺素浓度高之间可能存在相关性。
相似文献
1
Plasma concentrations of methimazole, a metabolite of carbimazole, in hyperthyroid patients.
Br J Clin Pharmacol. 1974 Jun;1(3):265-9. doi: 10.1111/j.1365-2125.1974.tb00248.x.
2
The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients.
Br J Clin Pharmacol. 1980 Feb;9(2):137-43. doi: 10.1111/j.1365-2125.1980.tb05823.x.
3
The pharmacokinetics of methimazole in a novel lipophilic formulation administered transdermally to healthy cats.
N Z Vet J. 2014 Jul;62(4):208-13. doi: 10.1080/00480169.2013.875990. Epub 2014 Feb 28.
4
Intrathyroidal iodide binding rates and plasma methimazole concentrations in hyperthyroid patients on small doses of carbimazole.
Br J Clin Pharmacol. 1981 Sep;12(3):315-8. doi: 10.1111/j.1365-2125.1981.tb01219.x.
5
6
Comparison of the disposition of carbimazole and methimazole in clinically normal cats.
Res Vet Sci. 1993 May;54(3):351-5. doi: 10.1016/0034-5288(93)90134-2.
7
Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients.
Endocrinol Jpn. 1986 Oct;33(5):605-15. doi: 10.1507/endocrj1954.33.605.
8
The efficacy and safety of a novel lipophilic formulation of methimazole for the once daily transdermal treatment of cats with hyperthyroidism.
J Vet Intern Med. 2011 Nov-Dec;25(6):1357-65. doi: 10.1111/j.1939-1676.2011.00799.x. Epub 2011 Sep 28.
9
Comparative bioavailability of carbimazole and methimazole.
Int J Clin Pharmacol Ther Toxicol. 1983 Oct;21(10):505-10.
10
Pharmacokinetics of controlled-release carbimazole tablets support once daily dosing in cats.
J Vet Pharmacol Ther. 2008 Jun;31(3):213-9. doi: 10.1111/j.1365-2885.2008.00949.x.
引用本文的文献
1
A patient-specific treatment model for Graves' hyperthyroidism.
Theor Biol Med Model. 2018 Jan 9;15(1):1. doi: 10.1186/s12976-017-0073-6.
2
Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.
Eur J Clin Pharmacol. 1982;21(5):379-84. doi: 10.1007/BF00542322.
3
Excretion of methimazole in human milk.
Eur J Clin Pharmacol. 1982 Oct;23(4):339-41. doi: 10.1007/BF00613617.
4
Pharmacokinetics of antithyroid drugs.
Klin Wochenschr. 1982 Jun 1;60(11):531-9. doi: 10.1007/BF01724208.
5
Clinical pharmacokinetics of antithyroid drugs.
Clin Pharmacokinet. 1981 Nov-Dec;6(6):401-28. doi: 10.2165/00003088-198106060-00001.
6
Influence of thyroid dysfunction on drug pharmacokinetics.
Clin Pharmacokinet. 1981 Jul-Aug;6(4):275-97. doi: 10.2165/00003088-198106040-00003.
7
Comparative In Vitro Effects and In Vivo Kinetics of Antithyroid Drugs.
Eur J Clin Pharmacol. 1980 Apr;17(4):295-9. doi: 10.1007/BF00625803.
8
Pharmacokinetic properties and bioavailability of methimazole.
Clin Pharmacokinet. 1985 Sep-Oct;10(5):443-50. doi: 10.2165/00003088-198510050-00006.
9
Pharmacokinetics of methimazole in humans.
Klin Wochenschr. 1985 Dec 2;63(23):1212-7. doi: 10.1007/BF01733780.
本文引用的文献
1
Antithyroid activity of 2-carbethoxythio-1-methylglyoxaline.
Lancet. 1951 Oct 6;2(6684):619-21. doi: 10.1016/s0140-6736(51)92892-9.
2
DETERMINATION AND IDENTIFICATION OF AMPHETAMINE IN URINE.
J Pharm Pharmacol. 1965 Jan;17:59-60. doi: 10.1111/j.2042-7158.1965.tb07570.x.
3
EFFECT OF THYROXINE ON THYROID UPTAKE OF THIOUREA-S35.
Proc Soc Exp Biol Med. 1964 Jan;115:64-6. doi: 10.3181/00379727-115-28832.
4
A fluorimetric assay for minute amounts of some thiohydantoins.
J Pharm Pharmacol. 1958 Dec;10(12):776-9. doi: 10.1111/j.2042-7158.1958.tb10372.x.
5
Development and comparison of thin-layer chromatographic and gas-liquid chromatographic methods for measurement of methimazole in rat urine.
J Chromatogr. 1970 Dec;53(2):285-91. doi: 10.1016/s0021-9673(01)98469-9.
6
Effect of thyroid hormone on the substrate interaction with P-450 in the oxidation of drugs by liver microsomes.
J Biochem. 1970 Nov;68(5):613-23. doi: 10.1093/oxfordjournals.jbchem.a129395.
7
Generic inequivalence--clinical observations.
Acta Pharmacol Toxicol (Copenh). 1971;29 Suppl 3:288-303. doi: 10.1111/j.1600-0773.1971.tb03308.x.
8
Methimazole: absorption, metabolism and excretion in the albino rat.
J Pharmacol Exp Ther. 1973 Feb;184(2):432-9.
9
The thyroid accumulation, oxidation and metabolic fate of 35 S-methimazole in the rat.
Endocrinology. 1972 Sep;91(3):747-56. doi: 10.1210/endo-91-3-747.
10
The acclumulation of 35 S-antithyroid drugs by the thyroid gland.
J Clin Endocrinol Metab. 1972 May;34(5):847-51. doi: 10.1210/jcem-34-5-847.
Zotero 插件